NKTアクチベータ、CD40アゴニスト、及び任意選択的に抗原を含んでなるアジュバント組合せと、細胞性免疫において相乗的な増強を誘導するためのその使用

Title:

Document Type and Number:

Japanese Patent JP5331100

Kind Code:

B2

Abstract:

Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (α-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers is also provided.

More Like This:

JP5762307	How to prevent influenza using a nasal vaccine
JP2021535730	MVA Vector and Its Use for Expression of Multiple Cytomegalovirus (CMV) Antigens
JP6285374	Vaccine nanotechnology

Inventors:

Ahonen, Collie
Noel, Randolph

Application Number:

JP2010506275A

Publication Date:

October 30, 2013

Filing Date:

April 25, 2008

Export Citation:

Click for automatic bibliography generation Help

Assignee:

Immuir X Incorporated

International Classes:

A61K39/39; A61K39/00; A61K39/02; A61K39/12; A61K39/35; A61K39/395; A61P35/00; A61P35/02; A61P37/04

Foreign References:

WO2003063899A1
WO2007007946A1
WO2006042177A1

Attorney, Agent or Firm:

Shinjiro Ono
Kazuo Shamoto
Yasushi Kobayashi
Akio Chiba
Hiroyuki Tomita
Takumi Terachi
Toshitaka Tsurugi

Previous Patent: JPS5331099

Next Patent: PRODUCTION OF FERULIC ACID